Article Figures & Data
Figures
- Figure 1.
Primary Endpoint Results
Both dose regimens of edoxaban were noninferior to warfarin in the primary noninferiority analysis. The high-dose regimen tended to be more effective at reducing stroke/SEE compared with warfarin and the low-dose regimen less effective.
Reproduced with permission from RP Giugliano, MD.
- Figure 2.
Secondary Endpoint Results
Both dose regimens of edoxaban reduced hemorrhagic stroke, death or ICH, and CV death compared with warfarin. The low-dose regimen was not as effective as warfarin at reducing ischemic stroke. CV=cardiovascular; E-60=edoxaban 60 mg QD dose group; E-30=edoxaban 30 mg QD dose group; ICH=intracerebral hemorrhage; SEE=systemic embolic events, TTR=time in therapeutic range.
Reproduced with permission from RP Giugliano, MD.
- Figure 3.
Key Safety Results
*Dose reduced by 50% in selected patients. Both dose regimens of edoxaban substantially reduced major, fatal, and intracranial bleeding. Gastrointestinal bleeding was increased with high-dose edoxaban compared with warfarin, but reduced with the low-dose regimen compared with warfarin. TTR=time in therapeutic range.
Reproduced with permission from RP Giugliano, MD.
Tools
Table of contents
Cited By...
- No citing articles found.